Compare AU
Compare DRUG vs. IOZ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the S&P Aussie 200 (IOZ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | IOZ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 704 |
Median incremental investment | $920.50 | $1,007.51 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,870.68 | $2,408.27 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | IOZ | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | The fund seeks to track the performance of the S&P/ASX 200 Accumulation Index before considering fees, expenses, and taxes. The index consists of the 200 largest Australian securities listed on the ASX. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | COMMONWEALTH BANK OF AUSTRALIA (10.56 %) BHP GROUP LTD (8.20 %) CSL LTD (5.53 %) |
Top 3 industries | Other (76.23 %) Communication Services (33.53 %) Health Care (23.66 %) | Financials (33.34 %) Materials (17.72 %) Health Care (8.77 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Australia (94.85 %) United States (3.08 %) New Zealand (1.58 %) |
Management fee | 0.57 % | 0.05 % |
Key Summary
DRUG | IOZ | |
|---|---|---|
Issuer | BetaShares | iShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P ASX 200 |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.05 % |
Price | $7.89 | $33.40 |
Size | $183.079 million | $6.278 billion |
10Y return | N/A | 42.61 % |
Annual distribution yield (5Y) | 1.90 % | 5.36 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 09/12/2010 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | IOZ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 704 |
Median incremental investment | $920.50 | $1,007.51 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,870.68 | $2,408.27 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | IOZ | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | IOZ |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |